Product news from the 10/03/06 News Brief

Share this article:
The FDA granted expanded indication to GlaxoSmithKline’s anti-seizure medicine Lamictal (lamotrigine) for treatment of Primary Generalized Tonic-Clonic (PGTC) seizures, also known as "grand mal" seizures, in children aged 2 and older and adults. Axcan Pharma said the FDA has issued an approval letter for the company's New Drug Application for Pylera (formerly Helizide). Pylera is a patented 3-in-1 capsule triple therapy, for the eradication of Helicobacter pylori, a bacterium recognized as being the main cause of gastric and duodenal ulcers. Gilead Sciences has agreed to acquire Myogen in a deal worth approximately $2.5 billion. The deal means that Gilead will acquire Myogen's main drug candidate, Ambrisentan, a pulmonary arterial hypertension treatment in late-stage clinical trials.
Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Business Briefs

Email Newsletters

MM&M Future Leaders


Register now

Early bird $1,950 before 31 October 2014

*Group discounts available on request 

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Business Briefs

Novartis said to be stepping out of HCV

Novartis is said to have relinquished rights to an investigational hep. C treatment, signaling its exit from the therapeutic space, according to a former partner's announcement.

Monday Moves: September 15

Hires and promotions for manufacturers, regulatory and agencies

Kantar acquires Evidências, expands Brazilian presence

The company's acquisition signals the growing importance of understanding the Brazilian healthcare market and evidence-based healthcare management services.